Treatment with novel oral anticoagulants: indications, efficacy and risks.


PURPOSE OF REVIEW To summarize data relevant to novel oral anticoagulants (nOACs), mainly apixaban, dabigatran and rivaroxaban, as alternatives to vitamin K antagonists (VKAs). RECENT FINDINGS RE-LY was the first contemporaneous study to compare a nOAC, dabigatran, with dose-adjusted warfarin, for prevention of stroke and systemic embolism in atrial… (More)
DOI: 10.1097/MOH.0b013e328363c170


  • Presentations referencing similar topics